Is lorlatinib/lorlatinib a domestic drug or an imported drug?

Lorlatinib/ Lorlatinib ( Lorlatinib) is developed and produced by Pfizer. It is an imported drug. It is mainly used to treat patients with ALK-positive non-small cell lung cancer (NSCLC), especially those who are resistant to other ALK inhibitors. Since lorlatinib was approved for marketing in many countries and regions around the world, it has been entering the market as an imported drug. It has also received drug approval in the Chinese market and has been included in the medical insurance reimbursement list.

Currently, there is no domestic version of lorlatinib in China, and Pfizer is its only manufacturer. Therefore, the price of lorlatinib in the Chinese market is relatively high, with the price of each box being approximately 20,000 yuan. The common specifications are 90 tablets of 25mg and 30 tablets of 100mg. After being included in China's medical insurance catalog, patients' drug costs can be reimbursed through medical insurance, which makes the use of lorlatinib more popular and reduces the financial burden on patients.

Although there is currently no domestically produced lorlatinib on the Chinese market, with the advancement of medical technology and the continuous advancement of research and development, a domestically produced version of lorlatinib may appear in the future. This will not only bring about price reductions, but also help improve drug availability for patients. In the future, if domestically produced lorlatinib is approved and marketed, its indications may be further expanded and treatment opportunities will be brought to more patients.

Despite its higher price, the efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer is unquestionable. Its introduction and use provide effective treatment options for the majority of patients with advanced lung cancer. Especially among drug-resistant patients, lorlatinib has demonstrated significant efficacy. In the future, with the development of more targeted drugs and the emergence of domestic drugs, treatment effects and drug prices may be further improved, helping more patients.

Reference materials：https://www.lorbrena.com/